JMP Securities Cuts Werewolf Therapeutics (NASDAQ:HOWL) Price Target to $4.00

Werewolf Therapeutics (NASDAQ:HOWL) had its price target cut by equities research analysts at JMP Securities from $12.00 to $4.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has a “market outperform” rating on the stock. JMP Securities’ price target suggests a potential upside of 187.77% from the stock’s previous close.

Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Werewolf Therapeutics in a research note on Tuesday, November 19th.

Werewolf Therapeutics Trading Up 3.0 %

Shares of NASDAQ:HOWL opened at $1.39 on Tuesday. The stock has a 50 day moving average of $1.75 and a 200 day moving average of $2.10. The company has a market cap of $61.94 million, a PE ratio of -0.91 and a beta of 0.38. Werewolf Therapeutics has a 12-month low of $1.31 and a 12-month high of $8.19. The company has a current ratio of 10.10, a quick ratio of 10.10 and a debt-to-equity ratio of 0.29.

Institutional Trading of Werewolf Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Millennium Management LLC boosted its stake in Werewolf Therapeutics by 96.4% in the 2nd quarter. Millennium Management LLC now owns 1,110,298 shares of the company’s stock worth $2,709,000 after purchasing an additional 544,881 shares during the period. PFM Health Sciences LP boosted its position in shares of Werewolf Therapeutics by 4.9% during the third quarter. PFM Health Sciences LP now owns 3,398,747 shares of the company’s stock worth $7,205,000 after acquiring an additional 157,673 shares during the last quarter. Marshall Wace LLP boosted its position in shares of Werewolf Therapeutics by 410.5% during the second quarter. Marshall Wace LLP now owns 134,184 shares of the company’s stock worth $327,000 after acquiring an additional 107,900 shares during the last quarter. Renaissance Technologies LLC grew its stake in Werewolf Therapeutics by 103.1% during the second quarter. Renaissance Technologies LLC now owns 171,000 shares of the company’s stock valued at $417,000 after acquiring an additional 86,800 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in Werewolf Therapeutics in the 2nd quarter valued at $165,000. Institutional investors own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.